NCT01458067View on ClinicalTrials.gov

A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 10, 2011

Primary Completion Date

November 12, 2015

Study Completion Date

February 25, 2016

Conditions
Cancer
Interventions
DRUG

GSK2636771

Oral capsules

Trial Locations (8)

37203

GSK Investigational Site, Nashville

73104

GSK Investigational Site, Oklahoma City

84112

GSK Investigational Site, Salt Lake City

06520

GSK Investigational Site, New Haven

110-744

GSK Investigational Site, Seoul

120/752

GSK Investigational Site, Seoul

SM2 5PT

GSK Investigational Site, Sutton

W1G 6AD

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01458067 - A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency | Biotech Hunter | Biotech Hunter